^(131)I-17-AAG治疗VX2兔前后IL-2、IL-4、IL-10和IFN-γ的变化

Changes of Serum IL-2, IL-4,IL-10 and IFN-γ Levels After Treatment with 131I-17-allylamino-17-demethoxygeldanamycin in VX2 Rabbit Models

目的:本文通过测定131I-17-丙烯胺基-17-脱甲基格尔德霉素(131I-17-AAG)治疗VX2肝癌兔模型前后血清白细胞介素2、4、10和IFN-γ的变化探讨对其自身免疫功能的影响。方法:以10mCi131I-17-AAG耳缘静脉注射治疗后1、2周,用放射免疫分析测定8例VX2肝癌兔模型血清中IL-2、IL-4、IL-10、IFN-γ水平,8例未经治疗的VX2肝癌兔模型作为对照。结果:IL-2、IFN-γ在1周时有显著性差异(P<0.05),2周时无显著性差异(P>0.05),IL-4、IL-10在1、2周均无显著性差异(P>0.05)。结论:131I-17-AAG治疗VX2肝癌兔模型对细胞免疫有暂时影响,但对体液免疫无影响,总体上说对VX2肝癌兔模型的治疗是安全的。

Objective To study the influence of ^131I - 17 - allylamino - 17 - demethoxygeldanamycin（ ^131I - 17 - A.AG） therapy on immune function in VX2 rabbit models with transplanted liver cancer. Methods Serum IL - 2, IL - 4, IL - 10 and IFN -γ levels were measured with RIA in 8 VX2 rabbit models with transplanted liver cancer 1 -2 weeks after 10mCi ^131I - 17 - AAG treatment as well as in 8 controls rabbits （models with tumor but without treatment）. Results 1 week after 10mCi ^131I treatment, the serum IL - 2 and IFN-γ levels were significantly lower in the treated rabbits than those in controls （ P 〈 0.05 ） , but the difference was not seen at 2 woeks after treatment（P 〉0,05）. Serum IL -4 and IL - 10 levels in the treated rabbits （both at 1 and 2 week） were not significantly different from those in controls （ P 〉 0.05 ）. Conclusion ^131I - 17 - A.AG treatment had transient effects on cellular immunity with no irfluenee on humoral immunity. As a whole, it is a safe to treat VX2 rabbit models with tiffs preparation.